If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
The peptide-loading complex (PLC) is a short-lived, multisubunit membrane protein complex that is located in the endoplasmic reticulum (ER). It orchestrates peptide translocation and selection by major histocompatibility complex class I (MHC-I) molecules. Stable peptide-MHC I complexes are released to the cell surface to promote T-cell response against malignant or infected cells. In turn, T-cells recognize the activated peptides, which could be immunogenic or non-immunogenic.
=== Artifacts === Artifacts are structures or features in tissue that interfere with normal histological examination. Artifacts interfere with histology by changing the tissues appearance and hiding structures. Tissue processing artifacts can include pigments formed by fixatives, shrinkage, washing out of cellular components, color changes in different tissues types and alterations of the structures in the tissue. An example is mercury pigment left behind after using Zenker's fixative to fix a section. Formalin fixation can also leave a brown to black pigment under acidic conditions.
254Es was used as the calibration marker in the chemical analysis spectrometer ("alpha-scattering surface analyzer") of the Surveyor 5 lunar probe. The large mass of this isotope reduced the spectral overlap between signals from the marker and the studied lighter elements of the lunar surface.
== Spectroscopy == Both the fluorescence excitation and emission spectrums of wild-type EosFP are shifted ~65 nm to the right upon excitation toward the red end of the spectrum. This spectral change is caused by an extension of the chromophore accompanied by a break in the peptide backbone between Phe-61 and His-62 in an irreversible mechanism. The presence of a crisp isosbestic point at 432 nm also suggests an interconversion between two species. An absorption peak at 280 nm is visible due to aromatic amino acids which transfer their excitation energy to the green chromophore. The quantum yield of the green-emitting form of Eos is 0.7. In the red shifted species, there are pronounced vibronic sidebands separate from the main peak at 533 nm and 629 nm in the excitation spectrum and emission spectrum respectively. There is another peak in the red excitation spectrum at 502 nm likely due to FRET excitation of the red fluorophore. The quantum yield of the red-emitting form is 0.55. EosFPs variants show almost no difference in spectroscopic properties, therefore, it is likely that the structural modifications which arise from separation of interfaces have little to no effect on the structure of the fluorophore-binding site.
== Later career and death == Cremer continued research at the University of Innsbruck and retired in 1971. She remained active in gas chromatography until almost the end of life. In 1990, an international symposium celebrating her work and her ninetieth birthday was held in Innsbruck. She died in 1996. In 2009, the University of Innsbruck established a program in her name which awards highly qualified women scientist in pursuit of a habilitation degree.
Sources: en.wikipedia.org
After dehydration, the mummy was wrapped in many layers of linen cloth. Within the layers, Egyptian priests placed small amulets to guard the decedent from evil. Once the mummy was completely wrapped, it was coated in resin in order to keep the threat of moist air away. The resin was also applied to the coffin in order to seal it. The mummy was then sealed within its tomb, alongside the worldly goods that were believed to help aid it in the afterlife. Aspergillus niger, a hardy species of fungus capable of living in various environments, has been found in the mummies of ancient Egyptian tombs and can be inhaled when they are disturbed.
Elevated waist circumference (population- and country-specific) Triglycerides ≥150 mg/dL (1.7 mmol/L) Reduced HDL-C (≤40 mg/dL (1.0 mmol/L) men; ≤50 mg/dL (1.3 mmol/L) women) Elevated blood pressure (systolic ≥130 and/or diastolic ≥85 mmHg) Fasting glucose ≥100 mg/dL (5.55 mmol/L) This statement recognises population differences in waist risk thresholds and encourages common criteria with agreed cut points for international comparisons. The prior IDF and revised NCEP definitions are similar, but differ on assumptions when body mass index ≥30 kg/m2 and on geography-specific waist cut points.
=== Addiction === Progesterone enhances the function of serotonin receptors in the brain, so an excess or deficit of progesterone has the potential to result in significant neurochemical issues. This link explains why some people resort to substances that enhance serotonin activity such as nicotine, alcohol, and cannabis when their progesterone levels fall below optimal levels.
== General and cited references == Sherman, Philip (1963). Rheology of Emulsions: Proceedings of a symposium held by the British Society of Rheology ... Harrogate, October 1962. British Society of Rheology / Macmillan. ISBN 9780080102900. Nalwa, H. S., ed. (2000). Handbook of Nanostructured Materials and Nanotechnology. Vol. 5. New York: Academic Press. pp. 501–575.
== Mechanisms of pathogenicity == The mechanisms of P. syringae pathogenicity can be separated into several categories: ability to invade a plant, ability to overcome host resistance, biofilm formation, and production of proteins with ice-nucleating properties.
Sources: en.wikipedia.org
In December 2020, Collins assisted with the launch of the free-to-play lottery app Bravospeed, for which she appeared in an online advertisement in academic dress explaining the app's rules. In July 2021, Collins teamed up with Durex alongside Ollie Locke and Alix Fox to create the Roadmap to Sexual Satisfaction, a guide in which she provided her tips and advice for getting physical, saying that "Confidence [was] the key to positive, satisfying, intimacy" and that "sexiness comes from within". In May 2022, Collins announced she was working with the brand again to support the launch of their new range of sex toys. She promoted three different vibrators and expressed the importance of "self-love" adding that the use of sex toys was "empowering" and that she wanted to help break the taboo around talking about them. In August 2021, Collins was announced as the new face of the laundry detergent brand Surf and released her own limited edition detergent and capsules as part of the company's "Diva Divine" range, exclusive to Asda supermarkets. In October 2021, Collins became a speaker at Big Business Events, a business development service in which she offered her tips for business growth and shared her own experiences during a 3-day live event. In November 2021, Collins announced her collaboration with Amazon Handmade, in which she worked with interior designers Paul Moneypenny and Siobhan Murphy to create a bespoke 33-piece collection featuring homeware, skincare and other gift items, titled the Gemma Collins & Friends Christmas Collection.
Alkaline phosphatase: Secreted by osteoblasts during active bone formation; elevated levels indicate increased osteoid production Osteocalcin: A bone-specific protein synthesized by osteoblasts and incorporated into osteoid; serves as a marker of bone formation Type I collagen peptides: Degradation products measured to assess bone turnover
=== 2006–2013: Rise to prominence and subsequent hiatus === Larter auditioned for the science fiction drama television series Heroes on NBC while living in Los Angeles. She played the characters of Niki Sanders, who suffered from dissociative identity disorder, and Tracy Strauss on the show created by Tim Kring. Larter's initial character Niki Sanders, was a wife, mother, and a former internet stripper from Las Vegas exhibiting superhuman strength and alternate personalities who go by the names of Jessica and Niki. "Ali read for the part and just owned it from the second she walked in," Kring said to the Chicago Tribune, "It was a very impressive audition." In the third and fourth seasons, Larter played the new character of Tracy Strauss, who possessed the ability to freeze objects and later, transform her body into water. Larter took on the title role in Marigold (2007), alongside Salman Khan, an Indian actor. The film was released in August 2007 and revolved around Marigold Lexington, an American actress (Larter) who goes to India and gets caught up in the exotic world of Bollywood. Filming took place in North India and London, commencing in June 2004. In an interview with the BBC, Larter remarked this role was "an opportunity to overcome my fear of singing and dancing because I have no professional training... I really focused on the character and loved this journey she went on and the experiences she had." She was paid a seven-figure salary for her part in the film.
== Diagnosis == Diagnosing autoimmune disorders can be complex due to the wide range of diseases within this category and their often overlapping symptoms. Accurate diagnosis is crucial for determining appropriate treatment strategies. Generally, the diagnostic process involves a combination of medical history evaluation, physical examination, laboratory tests, and, in some cases, imaging or biopsies.
PmF3 + 3 Li → Pm + 3 LiF The promethium sample produced was used to measure a few of the metal's properties, such as its melting point. In 1963, ion-exchange methods were used at ORNL to prepare about ten grams of promethium from nuclear reactor fuel processing wastes. Promethium can be either recovered from the byproducts of uranium fission or produced by bombarding 146Nd with neutrons, turning it into 147Nd, which decays into 147Pm through beta decay with a half-life of 11 days.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.